Transfusion and Apheresis Science最新文献

{"title":"Transiently acquired hemoglobin variants in patients with sickle cell disease: A case series and systematic review of the literature","authors":"Maha Al-Ghafry ,&nbsp;Abraham Haimed ,&nbsp;Tamara New ,&nbsp;Carrie Gann ,&nbsp;Sabrina Racine-Brzostek ,&nbsp;Jed B. Gorlin ,&nbsp;Cassandra D. Josephson ,&nbsp;Alexandra Jimenez","doi":"10.1016/j.transci.2025.104207","DOIUrl":"10.1016/j.transci.2025.104207","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with sickle cell disease (SCD) are transfused phenotypically-matched red blood cells (RBCs) for various indications. While screening for units that are sicklenegative is standard practice, the transfusion of RBCs containing other hemoglobin variants can be of concern to transfusion services and clinicians due to possible adverse events. Thus, this study aimed to review possible adverse events in patients with SCD with transiently acquired hemoglobin variants.</div></div><div><h3>Methods</h3><div>A case series of pediatric patients with SCD receiving chronic transfusions are presented, along with a systematic review of patients with SCD who were noted to have a transiently acquired hemoglobin variant. Data and patient outcomes were extracted and summarized.</div></div><div><h3>Results</h3><div>For the case series, 3 pediatric patients had transiently noted HbC peaks, with no adverse events documented. For the systematic review, 12 studies were included with a total of 75 patients with SCD. HbC was the most common hemoglobin variant in &gt; 90 %. Other variants noted were: HbD, HbJ, HbD/G, HbG- Philadelphia, HbA2’, and HbO-Arab. The maximum peak of reported variants was &lt; 20 % (14 % for HbC). No clinically significant adverse events were reported secondary to these transiently acquired variants.</div></div><div><h3>Conclusion</h3><div>Transiently acquired hemoglobin variants are commonly encountered in transfused patients with SCD, with no reported clinically significant adverse outcomes. Because phenotypic matching prioritizes donors with similar racial backgrounds, it increases the likelihood that the donor may carry hemoglobin variants. Blood centers and transfusion services should be aware of this phenomenon and avoid deferring donors with nonsickle hemoglobin variants.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 5","pages":"Article 104207"},"PeriodicalIF":1.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144653940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serological and secretor status analysis of Am phenotypes: Two cases from Northeast India","authors":"Joyisa Deb ,&nbsp;Priyanka Gogoi ,&nbsp;Gopal Krushna Ray ,&nbsp;Samim Sultana Hoque","doi":"10.1016/j.transci.2025.104205","DOIUrl":"10.1016/j.transci.2025.104205","url":null,"abstract":"<div><h3>Background</h3><div>In ABO blood grouping, a type II discrepancy refers to weak or absent antigen reactions in cell grouping, often indicating a weak ABO subgroup. The Am phenotype is a rare weak A subgroup variant, distinguished by absent agglutination with anti-A antisera and normal A substance in saliva. Reporting such rare phenotype is vital to improve awareness and diagnostic accuracy, especially in Northeast region of India, where access to advanced serological tools is limited.</div></div><div><h3>Case details</h3><div>During routine blood grouping, type II ABO discrepancies were noted in two cases. Comprehensive immunohematological workup, including cell grouping by conventional tube technique using different lectins and at varying temperatures, adsorption-elution studies, and secretor testing, was performed. Adsorption-elution studies confirmed weak A antigen expression. Secretor testing demonstrated the presence of A and H substances in saliva, consistent with Am phenotype.</div></div><div><h3>Conclusion</h3><div>Our cases highlight the diagnostic complexity of weak A subgroups. In resource-limited settings, with limited access to molecular diagnostics, detailed serological testing remains critical for ABO subgroup identification. Proper recognition of such phenotypes ensures transfusion safety and prevents misclassification.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 5","pages":"Article 104205"},"PeriodicalIF":1.4,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial DNA levels in plasma products: A comparative study of apheresis plasma from COVID-19 convalescent donors and apheresis and fresh frozen plasma from non-infected donors","authors":"Fatemeh Tavangar ,&nbsp;Azita Chegini ,&nbsp;Maryam Zadsar ,&nbsp;Shahram Samiee","doi":"10.1016/j.transci.2025.104203","DOIUrl":"10.1016/j.transci.2025.104203","url":null,"abstract":"<div><h3>Background</h3><div>Cellular and mitochondrial stress can trigger the extracellular release of mitochondrial DNA (mtDNA) as damage-associated molecular patterns (DAMPs), which may amplify inflammatory responses and contribute to transfusion-related adverse events. This study aimed to quantify mtDNA levels in plasma products, assess the effects of storage duration and preparation method (apheresis vs. FFP).</div></div><div><h3>Study design and methods</h3><div>A cross-sectional analysis was conducted from March 2022 to March 2023. Plasma samples included 16 units of fresh frozen plasma (FFP) obtained via whole blood centrifugation and 32 units of apheresis plasma collected using the Haemonetics MCS+ system. Apheresis donors were stratified into COVID-19-convalescent (n = 16) and non-infected (n = 16) groups. Convalescent donors had resolved mild-to-moderate infection for at least 30 days, confirmed by RT-PCR. mtDNA quantification was performed using real-time qPCR. Data were analyzed with GraphPad Prism 8 using appropriate parametric and non-parametric tests.</div></div><div><h3>Results</h3><div>Apheresis plasma from non-infected donors had the highest mean mtDNA concentration (2.3 × 10⁶ copies/mL), followed by convalescent plasma (8.2 × 10⁵ copies/mL) and FFP (6.0 × 10⁵ copies/mL). FFP mtDNA levels remained stable during storage, while apheresis plasma demonstrated a significant increase over 30 days. A moderate positive correlation was observed between mtDNA concentration and antibody titers in convalescent plasma.</div></div><div><h3>Conclusion</h3><div>mtDNA concentrations vary by plasma preparation method. These findings highlight the relevance of processing variables in transfusion safety and suggest mtDNA may serve as a molecular marker for product quality.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 5","pages":"Article 104203"},"PeriodicalIF":1.4,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The development and evanescence of red blood cell antibodies in a 51-year-old pregnant ovum recipient and her pregnancy outcome","authors":"Wenhao Xu ,&nbsp;Chunkang Chang","doi":"10.1016/j.transci.2025.104204","DOIUrl":"10.1016/j.transci.2025.104204","url":null,"abstract":"<div><div>Management of complications, including hemolytic disease of the fetus and newborn (HDFN) and identifying compatible red blood cell (RBC) for future transfusions, related to multiple RBC alloantibodies in extremely advanced age pregnant donor ovum (DO) recipient is a challenge for transfusion medicine, especially during emergencies when alloantibodies become evanescent. Here we reported a 51-year-old woman underwent three cycles of IVF using embryos from her husband sperm and anonymously DO. She was detected with anti-Ce and anti-Jk^a alloantibodies during the pregnancy, with anti-Jk^a becoming evanescent in the third trimester and reinduced after delivery. She had a postpartum hemorrhage of 1200 ml blood loss and transfused 2 units of 800 ml Rh and Kidd compatible RBC screened by Shanghai Blood Center. The newborn experienced moderate HDFN and was treated with phototherapy and intravenous immune globulin.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104204"},"PeriodicalIF":1.4,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of novel RASGRP2 mutations in patients with platelet dysfunction","authors":"Mohadese Heydarali Broojerdi ,&nbsp;Shadi Tabibian ,&nbsp;Rima Manafi Shabestari ,&nbsp;Mahmood Barati ,&nbsp;Mehrnoosh Shanaki ,&nbsp;Majid Safa","doi":"10.1016/j.transci.2025.104202","DOIUrl":"10.1016/j.transci.2025.104202","url":null,"abstract":"<div><h3>Background</h3><div>Inherited platelet function disorders (IPFDs) are rare hereditary diseases characterized by dysregulation of genes related to platelet receptors expression or signal transduction pathways. Bleeding disorder platelet-type 18 (BDPLT18) is an infrequent autosomal recessive platelet function disorder caused by <em>RASGRP2</em> mutation. The <em>RASGRP2</em> gene encodes calcium- and DAG-regulated guanine exchange factor-1 (CalDAG-GEFI), which plays a role in the activation of the αIIbβ3 integrin in platelets. In present study, eleven unrelated patients were examined for mutational analysis to identify mutations in <em>RASGRP2</em> gene that may lead to BDPLT18<strong>.</strong></div></div><div><h3>Methods</h3><div>The study included 11 unrelated cases (6 males and 5 females) with various bleeding disorders in 2024. The patients were selected based on normal expression of CD41, CD61, and CD42b, as well as an impaired response to ADP, collagen, and arachidonic acid. The plasma coagulation parameters of the patients were normal. Polymerase chain reaction (PCR) and sanger sequencing were used to screen for mutations in the <em>RASGRP2</em> gene.</div></div><div><h3>Results</h3><div>A total of 7 mutations were identified in the patients. Including four novel missense mutations (<em>RASGRP2</em>: p.F497L, p.F501L, p.N505K, p.C515G) and 3 known mutations (<em>RASGRP2</em>: p.D441N, p.R494Afs*54, g.10410 G&gt;T). These mutations are predicted to cause disease and alter the characteristics of the CalDAG-GEFI protein.</div></div><div><h3>Conclusion</h3><div>Identifying <em>RASGRP2</em> gene mutations and their association with bleeding episodes is crucial for confirming the diagnosis of BDPLT18, distinguishing it from other platelet disorders, and using effective therapeutics to prevent bleeding abnormalities.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104202"},"PeriodicalIF":1.4,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144595582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of iron levels and hematological indices among blood donors at the Southern Zonal Blood Center, Accra, Ghana","authors":"Samuel Antwi-Baffour ,&nbsp;Benjamin Tetteh Mensah ,&nbsp;Dorinda Naa Okailey Armah ,&nbsp;Hannah Nana Amene Asiedu ,&nbsp;Lawrence Annison","doi":"10.1016/j.transci.2025.104201","DOIUrl":"10.1016/j.transci.2025.104201","url":null,"abstract":"<div><h3>Background</h3><div>Blood donation is essential for maintaining life-saving supplies, but screening often focuses only on hemoglobin, neglecting iron stores. While hemoglobin recovers quickly, iron takes longer to replenish, putting frequent donors at risk. Even without anemia, low iron can cause fatigue, reduced endurance, and cognitive issues, potentially leading to iron-deficiency anemia. Many programs overlook iron status, leaving regular donors vulnerable to chronic depletion.</div></div><div><h3>Objective</h3><div>The objective of the study was to assess the iron status and haematological indices of categories of blood donors.</div></div><div><h3>Methods</h3><div>This cross-sectional study recruited 350 blood donors of which 146 were first-time donors, 146 repeat donors, and 58 hemoglobin-deferred donors from the Southern Zonal Blood Center, Accra, Ghana. For each participant, about 3 mL of blood sample was obtained to estimate FBC for haematological parameters and serum ferritin concentration for iron status.</div></div><div><h3>Results</h3><div>The study involved 350 blood donors and found a median Hb of 12.4 g/dL and ferritin levels ranging from 11.8 to 500 ng/mL. First-time donors showed a positively skewed Hb distribution, while repeat donors had greater variation with outliers. Significant differences (p &lt; 0.001) in Hb, MCV, MCHC, RDW, and serum ferritin were observed across the groups, though MCH showed no significant difference (p = 0.062). Iron depletion was present in 16.7 % of participants, whilst 8.3 % had iron-deficient erythropoiesis, and 75 % had normal ferritin levels.</div></div><div><h3>Conclusion</h3><div>The findings of the study highlight the differences in iron reserves and hematological parameters among donor categories, emphasizing the impact of donation frequency on iron status. This study provides new evidence from Ghana on how blood donation frequency affects iron reserves and haematological indices.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104201"},"PeriodicalIF":1.4,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotype pattern of factor V and XIII abnormalities in the Iranian population: A meta-analysis","authors":"Sadegh Abbasian ,&nbsp;Mojtaba Pouresmaeili Ravari ,&nbsp;Ali Sahebi ,&nbsp;Fatemeh Mezginejad","doi":"10.1016/j.transci.2025.104200","DOIUrl":"10.1016/j.transci.2025.104200","url":null,"abstract":"<div><h3>Background</h3><div>Hemostatic disorders are significantly associated with morbidity and mortality. Hence, the examination of coagulation abnormalities is a cornerstone of prevention and therapy. This meta-analysis aimed to determine the genotype pattern of Factor V (FV) and XIII (FXIII) abnormalities in the Iranian population. Methods The search strategy was conducted in electronic databases including Web of Science, PubMed, Scopus, SID, ProQuest, and Magiran, covering the period from May 10,1990, to May 10, 2019, following the PRISMA principles. Studies of various designs,including cross-sectional, cohort, experimental, and case-control studies, were included based on specific criteria, without any limitations on gender or language.Results Out of 10,449 research entries, 10,432 were screened, with 132 abstracts and titles analyzed, 23 full articles reviewed, and ultimately 11 studies included in the metaanalysis. The mutation c.1691 G&gt;A: GG (95 % CI: 0.98) had the greatest occurrence rate in FV deficient patients, while the 34Val/Leu mutation (95 % CI: 1.00) was detected as the most prevalent mutation in instances of FXIII insufficiency. Conclusions Specific FV and XIII gene mutations are associated with increased risk for thrombotic conditions. FV deficiency with the c.1691 G&gt;A mutation was prevalent in stroke patients, while FXIII deficiency with the 34Val/Leu mutation was linked to recurrent miscarriages.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104200"},"PeriodicalIF":1.4,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming ABO IgG titration: Real-world comparison of automated SPRCA vs. CAT with dithiothreitol (DTT) inactivation of IgM in 1600 ABO-incompatible solid organ transplant patient samples","authors":"Amena Ebadur Rahman ,&nbsp;Rasika Dhawan Setia ,&nbsp;Mitu Dogra ,&nbsp;Abhideep Chaudhary ,&nbsp;Ashwini Goel ,&nbsp;Amit Kumar Singhal ,&nbsp;Vadad ,&nbsp;Sonia Joseph ,&nbsp;Priyasha Prajapat","doi":"10.1016/j.transci.2025.104198","DOIUrl":"10.1016/j.transci.2025.104198","url":null,"abstract":"<div><div>Anti-ABO IgG isohemagglutinin(IHA) titration plays a vital role in guiding ABO-incompatible solid organ transplantation(ABOi-SOT). Column agglutination technology (CAT), though widely used, requires DTT pre-treatment to eliminate IgM interference. This poses significant challenges, including subjectivity, inconsistent IgM inactivation, frequent sample gelling, and prolonged turnaround times(TAT), all of which compromise accuracy and standardization. These limitations have prompted global interest in DTT-free, IgG-specific methods that enhance analytical precision and workflow efficiency.</div></div><div><h3>Study Design and Methods</h3><div>This prospective single-centre study (August 2019–October 2024) evaluated 1622 samples from 300 ABOi-SOT candidates; baseline titres done for all; 139 underwent transplantation. IgG titers were assessed via DTT-treated CAT [CAT(DTT)] and SPRCA during desensitization phase and post-transplant monitoring. IHA IgG titers were compared between CAT(DTT) and fully automated solid-phase red cell adherence assay (SPRCA). Concordance &amp; reproducibility was assessed using Pearson’s correlation and Cohen’s kappa and TATs compared.</div></div><div><h3>Results</h3><div>SPRCA showed strong correlation with CAT (DTT) for IgG titers (r = 0.949; κ = 0.71), with 91.4 % of values within ±1 dilution. Mean IgG TAT was significantly lower for SPRCA (65.26 ± 14.41 min) compared to CAT (DTT) (111.43 ± 19.5 min; p &lt; 0.0001). SPRCA demonstrated minimal inter-technologist variability and elimination of manual pre-DTT treatment steps translating to faster, more consistent results, enabling timely therapeutic decisions.</div></div><div><h3>Conclusion</h3><div>SPRCA is a robust, automated, and IgG-specific platform that overcomes key limitations of CAT. Its implementation in transplant workflows can enhance standardization, reduce delays, and support better outcomes, particularly critical in high-throughput ABOi transplant settings.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104198"},"PeriodicalIF":1.4,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144513526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating recurrent immune-mediated thrombotic thrombocytopenic purpura (iTTP) in pregnancy: A case report and literature review","authors":"Mohadese Golsorkhi ,&nbsp;Niloufar Ebrahimi ,&nbsp;Shahram Kordasti ,&nbsp;Sayna Norouzi ,&nbsp;Amir Abdipour","doi":"10.1016/j.transci.2025.104199","DOIUrl":"10.1016/j.transci.2025.104199","url":null,"abstract":"<div><div>Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and potentially fatal thrombotic microangiopathy characterized by thrombocytopenia and microangiopathic hemolytic anemia. It primarily affects women of childbearing age, with pregnancy being a significant precipitating factor. TTP overlaps with other pregnancy-related conditions, such as HELLP syndrome, complicating diagnosis and necessitating urgent clinical evaluation and intervention. Plasma-based therapies have significantly improved the prognosis for these patients. Additionally, serial follow-up of ADAMTS-13 activity is recommended at the preconception stage and throughout pregnancy for women with a history of TTP. In this report, we present a case of a 32-year-old patient with a recurrent iTTP on her 11-week gestation of the second pregnancy, which was successfully managed with therapeutic plasma exchange (TPE) and corticosteroids.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104199"},"PeriodicalIF":1.4,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma","authors":"Abdullah Karakus ,&nbsp;Ugur Hatipoglu ,&nbsp;Yavuz Katircilar ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Seda Yilmaz ,&nbsp;Gulsum Akgun Cagliyan ,&nbsp;Fahir Ozturk ,&nbsp;Emine Hidayet ,&nbsp;Sinan Demircioglu ,&nbsp;Mustafa Koroglu ,&nbsp;Ant Uzay ,&nbsp;Abdulkadir Basturk ,&nbsp;Suleyman Sami Karti ,&nbsp;Ahmet Sarici ,&nbsp;Servihan Unal ,&nbsp;Mehmet Sinan Dal ,&nbsp;Turgay Ulaş ,&nbsp;Serdal Korkmaz ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2025.104183","DOIUrl":"10.1016/j.transci.2025.104183","url":null,"abstract":"<div><h3>Background</h3><div>We conducted a multi-center retrospective non-randomized study to clarify roles of 2 and 3 gr/m² doses of Cyclophosphamide (Cy) for stem cell mobilization in Multiple Myeloma.</div></div><div><h3>Material and methods</h3><div>This study analyzed 169 adult patients who received Cy-based mobilization regimen at doses 2 and 3 gr/m² between 2018 and 2024. All patients included in this study were 18 years old and older. Patients divided into two groups; group 1 represents 2 gr/m² treated patients, and group 2 represents 3 gr/m² dosing. These two groups then compared in terms of CD34⁺ cell number collected by apheresis, apheresis days, peak peripheral blood CD34⁺ value and rates of mobilization failures.</div></div><div><h3>Results</h3><div>Higher doses of Cy yielded more hematopoietic stem cells compared to the lower dose Cy [10.00 (3.00–28.90) vs 9.01 (5.00–14.90), p = 0.002]; while mobilization failures and apheresis days were comparable across groups (p = 0.112 and p = 0.648, respectively). Apheresis days required for adequate stem cell harvest among groups was found statistically similar (p = 0.648).</div></div><div><h3>Conclusion</h3><div>This study indicated the superior efficacy of 3 gr/m² dose of Cy in terms of stem cell yield. However, mobilization failure and prolonged apheresis sessions were not issues with lower doses.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 4","pages":"Article 104183"},"PeriodicalIF":1.4,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}